American Family Children's Hospital
Paul M. Sondel, MD, PhD close
Paul M. Sondel, MD, PhD

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Paul M. Sondel, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Paul Sondel, M.D., Ph.D. is the Reed and Carolee Walker Professor in Pediatric Oncology at the University of Wisconsin – Madison. 
Dr. Sondel, a Milwaukee native, completed undergraduate and graduate education at UW-Madison leading to a Ph.D. in Genetics (1975), with guidance from Bone Marrow Transplant pioneer, Fritz Bach, M.D. He received his M.D. magna cum laude in 1977 from Harvard Medical School, while beginning his research in tumor immunology. Following pediatric residency training at the Universities of Minnesota and Wisconsin, he joined the faculty of UW-Madison in 1980 in the Departments of Pediatrics, Human Oncology and Genetics. He was promoted to professor in 1987, and became leader of the UW Carbone Cancer Center's Program in Immunology and Immunotherapy in 1990, when he also became Head of the Division of Pediatric Oncology.

Dr. Sondel has been a leader in scientific policy through multiple national committee roles, including The National Institutes of Health, The American Cancer Society, The Children's Oncology Group (COG), The National Cancer Institute, where he was a member of the Board of Scientific Counselors, and St. Jude's Children’s Research Hospital, where he was the Chair of their Scientific Advisory Committee and is now chair of their cancer center's external advisory board.

Clinically, he has worked with COG in contributing to the progress of the past 30 years in the development of curative treatments for childhood cancers. He is devoted to his own patients, and committed to leading a multidisciplinary team that is providing comprehensive and compassionate, state of the art treatment for all childhood cancer and hematology patients at the University of Wisconsin.


Pediatric Hematology and Oncology

UW Health Clinics

American Family Children's Hospital
(608) 263-6420 | (800) 323-8942 | Map

Hospital Affiliation(s)

American Family Children's Hospital (primary)
UnityPoint Health - Meriter (secondary)

UW School of Medicine and Public Health

Department of Pediatrics

Professional Certifications and Education

Board Certification Pediatrics
Fellowship Sidney Farber Cancer Institute, Boston, MA
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Minnesota Hospital and Clinics
Medical School Harvard Medical School, Boston, MA, 1977


Madison Magazine Top Docs 2016

Best Doctors® in America 2015

National Cancer Institute (NCI) Outstanding Investigator Award 2015

Newsweek's Top Cancer Doctors 2015

Best Doctors® in America 2014

Best Doctors® in America 2013

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.


Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.

Programs & Conditions

Dr. Sondel's research has emphasized the translation of laboratory innovations into clinical progress. His laboratory has pursued the biology of graft-versus-leukemia reactions, activation of anti-tumor immune destruction with Interleukin-2 and the use of tumor reactive monoclonal antibodies to facilitate tumor killing by lymphocytes. These studies have all moved into clinical testing led by Dr. Sondel at UW, and in national studies he has led through the Children’s Oncology Group (COG).

He has published more than 360 scientific articles and chapters, and his laboratory has provided training for 58 graduate students and post-doctoral fellows.

Learn more about Dr. Sondel's research: UW-Madison Department of Genetics | Sondel Laboratory

PubMed Articles
Neri D Sondel PM . Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol. 2016 Jun;40:96-102
[PubMed ID: 27060634]
Albertini MR Ranheim EA Zuleger CL Sondel PM Hank JA Bridges A Newton MA McFarland T Collins J Clements E Henry MB Neuman HB Weber S Whalen G Galili U . Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma. Cancer Immunol Immunother. 2016 May 20;
[PubMed ID: 27207605]
Kohrt HE Tumeh PC Benson D Bhardwaj N Brody J Formenti S Fox BA Galon J June CH Kalos M Kirsch I Kleen T Kroemer G Lanier L Levy R Lyerly HK Maecker H Marabelle A Melenhorst J Miller J Melero I Odunsi K Palucka K Peoples G Ribas A Robins H Robinson W Serafini T Sondel P Vivier E Weber J Wolchok J Zitvogel L Disis ML Cheever MA . Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer. 2016;4:15
[PubMed ID: 26981245]
Erbe AK Wang W Gallenberger M Hank JA Sondel PM . Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells. Methods Mol Biol. 2016;1441:43-56
[PubMed ID: 27177655]
Jensen JL Rakhmilevich A Heninger E Broman AT Hope C Phan F Miyamoto S Maroulakou I Callander N Hematti P Chesi M Bergsagel PL Sondel P Asimakopoulos F . Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunol Res. 2015 Aug;3(8):881-90
[PubMed ID: 25941352]
Shi Y Felder MA Sondel PM Rakhmilevich AL . Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages. Mol Immunol. 2015 Aug;66(2):208-15
[PubMed ID: 25829245]
Goldberg JL Sondel PM . Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Semin Oncol. 2015 Aug;42(4):562-72
[PubMed ID: 26320061]
McDowell KA Hank JA DeSantes KB Capitini CM Otto M Sondel PM . NK cell-based immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol. 2015 Mar;37(2):79-93
[PubMed ID: 25590232]
Wang W Erbe AK Hank JA Morris ZS Sondel PM . NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol. 2015;6:368
[PubMed ID: 26284063]
Sheridan RT Hudon J Hank JA Sondel PM Kiessling LL . Rhamnose glycoconjugates for the recruitment of endogenous anti-carbohydrate antibodies to tumor cells. Chembiochem. 2014 Jul 7;15(10):1393-8
[PubMed ID: 24909955]
Navid F Sondel PM Barfield R Shulkin BL Kaufman RA Allay JA Gan J Hutson P Seo S Kim K Goldberg J Hank JA Billups CA Wu J Furman WL McGregor LM Otto M Gillies SD Handgretinger R Santana VM . Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol. 2014 May 10;32(14):1445-52
[PubMed ID: 24711551]
Capitini CM Otto M DeSantes KB Sondel PM . Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol. 2014;10(9):1659-78
[PubMed ID: 25145434]
Qu X Felder MA Perez Horta Z Sondel PM Rakhmilevich AL . Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. Int Immunopharmacol. 2013 Dec;17(4):1141-7
[PubMed ID: 24201083]
Yang RK Kalogriopoulos NA Rakhmilevich AL Ranheim EA Seo S Kim K Alderson KL Gan J Reisfeld RA Gillies SD Hank JA Sondel PM . Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunol Immunother. 2013 Aug;62(8):1303-13
[PubMed ID: 23661160]
Alderson KL Luangrath M Elsenheimer MM Gillies SD Navid F Rakhmilevich AL Sondel PM . Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG. Cancer Immunol Immunother. 2013 Apr;62(4):665-75
[PubMed ID: 23151945]
Van De Voort TJ Felder MA Yang RK Sondel PM Rakhmilevich AL . Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. J Immunother. 2013 Jan;36(1):29-40
[PubMed ID: 23211623]
Albertini MR Hank JA Gadbaw B Kostlevy J Haldeman J Schalch H Gan J Kim K Eickhoff J Gillies SD Sondel PM . Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunol Immunother. 2012 Dec;61(12):2261-71
[PubMed ID: 22678096]
Rakhmilevich AL Baldeshwiler MJ Van De Voort TJ Felder MA Yang RK Kalogriopoulos NA Koslov DS Van Rooijen N Sondel PM . Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunol Immunother. 2012 Oct;61(10):1683-97
[PubMed ID: 22392192]
Yang RK Kalogriopoulos NA Rakhmilevich AL Ranheim EA Seo S Kim K Alderson KL Gan J Reisfeld RA Gillies SD Hank JA Sondel PM . Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol. 2012 Sep 1;189(5):2656-64
[PubMed ID: 22844125]
Rakhmilevich AL Alderson KL Sondel PM . T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol. 2012 Aug;31(4):267-78
[PubMed ID: 22804571]